Table 4 |
||||
Effect of analgesic treatment on canine brief pain inventory (CBPI) questionnaire scores | ||||
ABT-116 (n = 13) | Carprofen (n = 12) | Tramadol (n = 12) | Placebo (n = 12) | |
Total CBPI Score | −20.3 ± 39.5 | −40.6 ± 34.9** | −38.5 ± 30.0*** | −13.5 ± 42.7 |
Statistical Power | 0.07 | 0.37 | 0.36 | |
Sample Size for Power > 0.8 | n = 580 | n = 34 | n = 35 | |
Pain Severity Score | −15.3 ± 45.0 | −39.4 ± 34.5** | −24.9 ± 39.0 | −14.7 ± 43.7 |
Statistical Power | 0.05 | 0.32 | 0.19 | |
Sample Size for Power > 0.8 | n > 1,000 | n = 41 | n = 260 | |
Pain Interference Score | −20.1 ± 44.8 | −41.8 ± 37.3** | −47.2 ± 29.2*** | −12.6 ± 44.4 |
Statistical Power | 0.07 | 0.39 | 0.60 | |
Sample Size for Power > 0.8 | n = 500 | n = 32 | n = 19 |
Note: Data represent percentage change in Week 3 of the trial, compared with mean baseline. Power analysis results compare each treatment group with placebo. Significance of changes in questionnaire scoring from mean baseline to end of the trial is indicated as follows: ** - P ≤ 0.01; *** - P ≤ 0.001.
Malek et al.
Malek et al. BMC Veterinary Research 2012 8:185 doi:10.1186/1746-6148-8-185